Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tavazzi, L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Tavazzi, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Heart rate as a therapeutic target in heart failure?

L. Tavazzi*

Department of Cardiology, Policlinico San Matteo, Institute of Care and Research, Pavia, Italy

* Prof. Luigi Tavazzi, Divisione di Cardiologia, IRCCS Policlinico San Matteo, P.le Golgi, 2, 27100 Pavia, Italy.

Abstract

A common finding in all clinical trials on heart failure is a negative correlation between heart rate and duration of life. In several studies this was found in both patients taking and those not taking beta-blocker agents. In postinfarct patients increasing mortality with increasing heart rate was found in the absence and in the presence of left ventricular dysfunction. Moreover beneficial effects of neurohormonal modulators were found to be greater in heart failure patients with higher heart rate. Thus heart rate can be considered a target for medical intervention, and therapeutic attempts focused on direct control of heart rate have a good rationale.

Key Words: Heart rate • Heart failure • If channel • channel antagonist • Ivabradine


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart J SupplHome page
P. G. Steg
Overview of large morbidity/mortality trials with ivabradine: focus on the BEAUTIfUL study
Eur. Heart J. Suppl., September 1, 2007; 9(suppl_F): F15 - F19.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.